WASHINGTON--(BUSINESS WIRE)-- TheMilken Institute is launching a resource to help the public and policymakers track progress in the development of treatments and vaccines for COVID-19.

The tracker is available online at https://milkeninstitute.org/covid-19-tracker. It is developed and maintained by FasterCures, a center of the Milken Institute, with an Advisory Council comprised of a Nobel Laureate researcher, former FDA chiefs, and industry leaders.

“We seek to accelerate efforts to find new treatments or vaccines, amplify what’s working, hold the system and its players accountable, and expand the global discussion about how to create durable, long term solutions,” says Esther Krofah, executive director of FasterCures. “COVID-19 is putting that approach to the test. We hope to be a resource promoting effective approaches and strategies.”

The Milken Institute COVID-19 vaccine development and treatment tracker is compiled from publicly available sources. It will grow to include FDA-approved indications where applicable, as well as basic information about the focus of each clinical trial.

The information in the tracker is current as of March 18, 2020. The Milken Institute welcomes input on new treatments and vaccines in development. Please email COVID19@milkeninstitute.org with tips.

About FasterCures

FasterCures, a center of the Milken Institute, is working to build a system that is effective, efficient, and driven by a clear vision: patient needs above all else. We believe that transformative and life-saving science should be fully realized and deliver better treatments to the people who need them.

About the Milken Institute

The Milken Institute is a nonprofit, nonpartisan think tank that helps people build meaningful lives, in which they can experience health and well-being, pursue effective education and gainful employment, and access the resources required to create ever-expanding opportunities for themselves and their broader communities. For more information, visit https://milkeninstitute.org/

View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005170/en/